HLN.L

Haleon plc
Haleon PLC - Haleon plc: EMTN bond offering
12th September 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8576D
Haleon PLC
12 September 2024
 

 

Icon Description automatically generated

 

Haleon plc: EMTN bond offering

 

12 September 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that, on 11 September 2024, its wholly-owned subsidiary, Haleon UK Capital plc, successfully priced two notes under its Euro Medium Term Note ("EMTN") programme (the "Offering"). The Offering is expected to close on 18 September 2024, subject to customary closing conditions.

 

The Offering consisted of the following notes, issued by Haleon UK Capital plc and fully and unconditionally guaranteed by the Company:

 

·      €750,000,000 of fixed rate notes with a coupon of 2.875% maturing on 18 September 2028; and

 

·      £300,000,000 of fixed rate notes with a coupon of 4.625% maturing on 18 September 2033 (together, the "Notes")

 

The Company expects to use the net proceeds of the Offering for general corporate purposes including partial repayment of the $1.75bn bond maturing in March 2025.

 

Barclays, Bank of America, BNP Paribas and JP Morgan acted as joint book-running managers on the transaction.

 

The Notes will be issued under Haleon UK Capital plc's and Haleon Netherlands Capital B.V.'s £10,000,000,000 EMTN programme and admitted to trading on the International Securities Market of the London Stock Exchange.

 

The Notes have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration.

 

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the Notes described herein, nor shall there be any sale of these Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

 

 

Amanda Mellor 

Company Secretary 

 

 

Enquiries

 

Investors

Media

 

Sonya Ghobrial  

+44 7392 784784

Zoë Bird

+44 7736 746167

Rakesh Patel     

+44 7552 484646

Gemma Thomas

+44 7985 175048

Emma White

+44 7823 523562



 

Email: investor-relations@haleon.com

 

Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com. 

 

 

                        

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IODLBMLTMTABBFI]]>
TwitterFacebookLinkedIn